Skimmianine (2) shows potential in the treatment of Alzheimer’s disease due to its ability to inhibit acetylcholine esterase (AChE) and the production of nitric oxide (NO), which can influence inflammation within the nervous tissue [1]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.